Journal article
Observed cost and variations in short term cost-effectiveness of therapy for ischemic stroke in Interventional Management of Stroke (IMS) III
KN Simpson, AN Simpson, PD Mauldin, YY Palesch, SD Yeatts, D Kleindorfer, TA Tomsick, LD Foster, AM Demchuk, P Khatri, MD Hill, EC Jauch, TG Jovin, B Yan, RV Kummer, CA Molina, M Goyal, WJ Schonewille, M Mazighi, ST Engelter Show all
Journal of the American Heart Association | Published : 2017
Abstract
Background- Examination of linked data on patient outcomes and cost of care may help identify areas where stroke care can be improved. We report on the association between variations in stroke severity, patient outcomes, cost, and treatment patterns observed over the acute hospital stay and through the 12-month follow-up for subjects receiving endovascular therapy compared to intravenous tissue plasminogen activator alone in the IMS (Interventional Management of Stroke) III Trial. Methods and Results- Prospective data collected for a prespecified economic analysis of the trial were used. Data included hospital billing records for the initial stroke admission and subsequent detailed resource ..
View full abstractGrants
Awarded by Boehringer Ingelheim
Funding Acknowledgements
This work was supported by NIH/NINDS grant numbers: UC U01NS052220, U01NS054630, and U01NS077304. Genentech Inc supplied study drug used for intra-arterial tPA in the Endovascular group. EKOS Corp, Concentric Inc, and Cordis Neurovascular, Inc supplied study catheters during Protocol Versions 1 to 3. In the United States, IMS III investigator meeting support was provided, in part, by Genentech Inc, EKOS Corp, and Concentric Inc. In Europe, IMS III investigator meeting support was provided, in part, by Boehringer Ingelheim. This publication was partially supported by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH-NCATS Grant Number UL1 TR001450. Data support for the study was provided through the CEDAR core funded by the MUSC Office of the Provost.